Creative Biolabs

Aptamer modified Liposome Development Service for Targeted Drug Delivery

At Creative Biolabs, we bridge the gap between potent therapeutic payloads and their precise biological targets through our advanced aptamer-functionalized liposomal platforms. By leveraging high-affinity aptamers as "chemical antibodies", we engineer smart delivery vehicles capable of navigating complex biological barriers to reach specific microorganism, cells, tissues, or organelles. Our dedicated team combines cutting-edge Module Delivery Systems with proprietary conjugation technologies, establishing Creative Biolabs as a premier partner in the development of next-generation precision medicines.

Start Your Aptamer-modified Liposomes Project

The Science of Aptamer-modified Liposomes

The Power of Aptamers in Targeting

Aptamers are short, single-stranded DNA or RNA oligonucleotides selected via Systematic Evolution of Ligands by Exponential Enrichment to bind targets with high affinity and specificity. Unlike protein-based antibodies, aptamers offer superior tissue penetration due to their smaller size, lower immunogenicity, and exceptional chemical stability. They can be engineered to recognize a vast array of targets, from cell surface receptors (e.g., Nucleolin, PSMA) to specific small molecules.

Fig. 1 Selection procedure of cell-internalizing DNA aptamer using cell-SELEX.1,3

Aptamers-mediated Targeted Drug Delivery Strategies

To utilize the precise targeting capabilities of aptamers, therapeutic strategies are generally categorized into two primary approaches. Creative Biolabs specializes in the optimization of these systems to maximize the therapeutic index.

Aptamer-modified Liposomes

Schematic diagram of the structure of aptamer-conjugated liposomes. (Creative Biolabs Original)

By anchoring aptamers to the surface of a liposome, we combine the high specificity of the aptamer with the extensive payload capacity of the lipid vesicle. This hybrid system provides a protective shell for labile cargoes (such as mRNA or siRNA) and facilitates the delivery of a high concentration of therapeutic molecules per binding event.

Aptamer-Drug Conjugates (ApDCs)

Targeted drug delivery based on ApDCs. (Creative Biolabs Original)

This strategy involves the direct covalent linkage of a therapeutic agent to a specific aptamer sequence. By utilizing the intrinsic affinity of the aptamer for a target receptor, the drug is guided directly to the site of action.

Advantages of Aptamer-modified Liposomes

Integrating aptamers into liposomal formulations offers distinct advantages over conventional passive targeting (EPR effect) or antibody-based targeting:

Fig. 2 Aptamer-mediated targeted drug delivery system.2,3

Common Aptamers for Liposome Modification

Aptamers act as precise molecular guides when conjugated to liposomes. By selecting sequences that specifically recognize overexpressed receptors on diseased cells, researchers can achieve highly targeted delivery. The following table lists several well-characterized aptamers commonly employed to functionalize liposomes for therapeutic applications:

Aptamer Target Application
A10 / A9 (RNA) PSMA (Prostate-Specific Membrane Antigen) Prostate cancer targeting
Sgc8 (DNA) PTK7 (Protein Tyrosine Kinase 7), CCRF-CEM cell Leukemia (T-cell ALL), Colon cancer, A549 cells
Endo28 (DNA) Annexin A2 Ovarian cancer
FKN-S2 (DNA) Fractalkine Colon adeno-carcinoma
ACE4 Annexin A2 MCF-7 cells
SRZ1 (DNA) 4T1 cells Breast cancer
EpCAM-Ap EpCAM Colorectal Cancer
XEO2mini (RNA) PC3 cells Prostate cancer
5TR1 (DNA) Mucin-1 MCF-7 and C26 cells
AIR-3A (RNA) IL-6R IL-6R-carrying cells
AS-14 (DNA) Fibronectin protein Ehrlich carcinoma
FKN-S2 (DNA) Fractalkine Colon adeno-carcinoma
TLS1c (DNA) MEAR cells Hepatoma
S15 (DNA) NSCLC A549 cells
HB5 (DNA) HER2 SK-BR-3 cells

Comprehensive Aptamer-modified Liposome Development Services

Request a Consultation

Creative Biolabs provides end-to-end solutions for the design, synthesis, and characterization of aptamer-modified liposomes. We have structured our services to address the specific needs of advanced drug delivery research.

Before conjugation, securing high-quality ligands is critical. We offer comprehensive upstream services to generate and optimize aptamers for your specific targets.

  • Custom Aptamer Screening: Selection of high-affinity aptamers against cell surface markers, proteins, or small molecules using aptamer screening protocols.
  • Sequence Optimization: Truncation and mutagenesis studies to identify the minimal binding motif, enhancing synthesis efficiency and reducing steric bulk.
  • Chemical Stabilization: Incorporation of modified nucleotides (e.g., 2'-OMe, 2'-F) to enhance nuclease resistance and in vivo stability.

We employ precise conjugation chemistries to ensure optimal ligand presentation.

  • Conjugation Strategies: We offer Post-insertion and Pre-insertion methods using Thiol-Maleimide, EDC/NHS, or Click Chemistry (DBCO-Azide) linkers.
  • Spacer Optimization: Inclusion of PEG spacers of varying lengths to reduce steric hindrance and improve aptamer flexibility for receptor binding.

Our encapsulation protocols are tailored to the physicochemical properties of your cargo.

  • Nucleic Acids: Efficient loading of siRNA, miRNA, mRNA, and CRISPR/Cas9 RNP complexes using microfluidic mixing or ethanol injection.
  • Small Molecules & Proteins: Remote loading (pH gradient) for amphipathic drugs (e.g., Doxorubicin) and passive loading for proteins or hydrophobic compounds.

We don't just synthesize; we validate.

  • Physical Analysis: Size (DLS), Zeta Potential, Morphology (Cryo-TEM), and Encapsulation Efficiency (HPLC/RiboGreen).
  • In Vitro Validation: Assessment of cellular uptake and binding affinity utilizing Flow Cytometry and Confocal Microscopy in relevant cell lines.

Lyophilization & Stability Formulation

Lyophilization & Stability Formulation (Creative Biolabs Authorized)

To ensure logistical feasibility, we develop robust freeze-dried formulations.

  • Cryoprotectant Screening: Optimization of Cryoprotectant ratios to prevent liposome fusion or leakage during lyophilization.
  • Stability Testing: Accelerated stability studies to determine shelf-life and storage conditions.
Precision Liposome Development

Workflow

Our workflow. (Creative Biolabs Original)

Revolutionizing Research with Aptamer-modified Liposomes

Why Choose Creative Biolabs?

Request a Technical Consultation with Our Experts

Proprietary Module Delivery Systems

We utilize a modular platform that allows for rapid "mix-and-match" optimization of lipid backbones and aptamer ligands to suit specific therapeutic goals.

High-Fidelity Conjugation

Our optimized chemistry ensures high ligand density (aptamers/liposome) without compromising the tertiary structure or biological activity of the aptamer.

Scalability & Stability

We bridge the gap between discovery and development, offering scalable production and proprietary lyophilization protocols for shelf-stable, Aptamer-Conjugated Liposome products.

Expert Scientific Support

Our team acts as an extension of your lab, providing deep technical insights on aptamer selection, linker chemistry, and troubleshooting throughout the project.

Customization Flexibility

We tailor every aspect—size, charge, payload, and linker strategy—to your specific biological question.

At Creative Biolabs, we are dedicated to advancing the frontiers of precision medicine. By integrating high-affinity aptamers with robust liposomal delivery systems, we provide researchers with the tools to solve critical bioavailability and targeting challenges.

Related Services

FAQs

How does aptamer targeting compare to antibody targeting in liposomal formulations?

While both provide active targeting, aptamers in Aptamer-Conjugated Liposomes often exhibit higher stability and lower immunogenicity. Aptamers are smaller, allowing for better tumor penetration, and their chemical synthesis ensures high batch-to-batch consistency compared to biological antibody production.

Can your Aptamer-Conjugated Liposomes encapsulate both hydrophilic and hydrophobic drugs?

Yes. Our hybrid systems are designed with a lipid bilayer (ideal for hydrophobic drugs like Paclitaxel) and an aqueous core (ideal for hydrophilic drugs like Doxorubicin), allowing for the co-delivery of synergistic therapies within a single targeted vehicle.

What is the stability of your aptamer-modified liposomes?

Liquid formulations are typically stable for weeks at 4°C. However, we highly recommend our Lyophilization Service for long-term storage. Our specialized freeze-drying protocols preserve the structural integrity of the liposome and the binding affinity of the aptamer for months to years.

Do you offer scale-up services for animal studies?

Absolutely. We can scale production from milligram quantities for in vitro screening to gram-scale batches suitable for in vivo preclinical efficacy and toxicology studies.

References

  1. Fu, Zhaoying, and Jim Xiang. "Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy." International journal of molecular sciences 21.23 (2020): 9123. https://doi.org/10.3390/ijms21239123.
  2. Yan, Shuxin, et al. "Different targeting ligands-mediated drug delivery systems for tumor therapy." Pharmaceutics 16.2 (2024): 248. https://doi.org/10.3390/pharmaceutics16020248.
  3. Distributed under Open Access license CC BY 4.0, without modification.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations